Our latest blog covers how to better understand the role of the AATB in response to FDA’s recent guidance on Mtb and Sepsis

In our latest blog, we explore how the National Institute of Standards and Technology ties to our industry more so than you may think.

Reviewing the FDA’s guidance “Recommendations to Reduce the Risk of Transfusion-Transmitted Malaria” and how it affects the Tissue Banking Industry.

Our next blog covers navigating the CDC website and other resources within our industry

This blog is an in-depth look at navigating the FDA website

Our latest blog highlights the challenges and risk mitigation tools needed to successfully navigate Supply Chain considerations

Here is the latest FDA Guidance on Hepatitis C and its impact to our Industry

Read here about the Food and Drug Administration’s (FDA) updates for Hepatitis B Virus (HBV)

Here is the latest highlight on Human Immunodeficiency Virus (HIV) and its impact to the Human Tissue industry

Here is our latest blog the FDA Guidance document: “Recommendations to Reduce the Risk of Transmission of Disease Agents with Sepsis by Human Cells, Tissues, and Cellular and Tissue Based Products (HCT/Ps)

Delayed implementation of 5/4/25

Here is our newest blog on the FDA guidance document:

“Recommendations to Reduce the Risk of Transmission of Mycobacterium tuberculosis (Mtb) by Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps)”.

Background information on the implementation delay from the FDA with regard to Sepsis and Mtb.

A quick overview of the most recent FDA Guidance Documents for HCT/Ps!

Here is how your organization can adjust to the recent AATB 24-1 Bulletin